Nakagome Kazuyuki, Nagata Makoto
Department of Respiratory Medicine, Saitama Medical University, 38 Morohongo, Moroyama-cho, Iruma-gun, Saitama, Japan.
Auris Nasus Larynx. 2011 Oct;38(5):555-63. doi: 10.1016/j.anl.2011.01.011. Epub 2011 Feb 19.
Bronchial asthma is a chronic disorder characterized by airway inflammation, reversible airway obstruction, and airway hyperresponsiveness. Eosinophils are believed to play important roles in the pathogenesis of asthma through the release of inflammatory mediators. In refractory eosinophilic asthma, anti-IL-5 mAb reduces exacerbations and steroid dose, indicating roles of eosinophils and IL-5 in the development of severe eosinophilic asthma. Even in the absence of IL-5, it is likely that the "Th2 network", including a cascade of vascular cell adhesion molecule-1/CC chemokines/GM-CSF, can sufficiently maintain eosinophilic infiltration and degranulation. Cysteinyl leukotrienes can also directly provoke eosinophilic infiltration and activation in the airways of asthma. Therefore, various mechanisms would be involved in the eosinophilic airway inflammation of asthma. In the pathogenesis of severe asthma, not only eosinophils but also mast cells or neutrophils play important roles. Mast cells are much infiltrated to smooth muscle in severe asthma and induce airway remodeling by release of inflammatory mediators such as amphiregulin. Treatment with anti-IgE Ab, which neutralizes circulating IgE and suppresses mast cell functions, reduces asthma exacerbations in severe asthmatic patients. Furthermore, infiltration of neutrophils in the airway is also increased in severe asthma. IL-8 plays an important role in the accumulation of neutrophils and is indeed upregulated in severe asthma. In the absence of chemoattractant for eosinophils, neutrophils stimulated by IL-8 augment the trans-basement membrane migration of eosinophils, suggesting that IL-8-stimulated neutrophils could lead eosinophils to accumulate in the airways of asthma. In view of these mechanisms, an effective strategy for controlling asthma, especially severe asthma, should be considered.
Auris Nasus Larynx. 2011-10
Front Immunol. 2018-9-28
Eur J Respir Dis Suppl. 1983
Verh K Acad Geneeskd Belg. 2003
Expert Rev Clin Immunol. 2006-1
Res Rep Health Eff Inst. 2003-12
Zhonghua Jie He He Hu Xi Za Zhi. 1998-11
Front Med (Lausanne). 2025-5-8
Parasites Hosts Dis. 2024-8
Pathophysiology. 2024-5-27
Allergy Asthma Immunol Res. 2023-3
Evid Based Complement Alternat Med. 2022-8-22